Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twin SUBLIVAC Grasses Efficacy Study
NCT00422149Phase 3Completed
- Sponsor
- HAL Allergy Group
- Start
- Sep 2006
- Primary completion
- Oct 2007
- Modality
- Allergy Immunotherapy
- Countries
- 4
01
Overview
A Phase 3 trial of Sublivac Grasses in allergic rhinoconjunctivitis (ARC), asthma, sponsored by HAL Allergy Group. Started Sep 2006; status: completed.
02
Drugs
Sublivac Grasses
03
Conditions
allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on NCT00422149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00422149.